Glioblastoma (GB) is the most common and aggressive malignant brain tumor, with a median survival of only 12–15 months.
Alternative therapeutic strategies—such as targeting the mitogen-activated protein kinase/extracellular signal-regulated kinase (MAPK/ERK) signaling pathway with MEK inhibitors like trametinib and selumetinib—are being explored.
However, their clinical success is currently hindered by inadequate delivery across the blood–brain barrier and dose-limiting toxicity.
In this work, Noemi Bognanni, Graziella Vecchio and colleagues investigate two cationic CyD polymers as potential nanocarriers for GB therapy based on trametinib and selumetinib.
Their multivalent architecture and positive charge can facilitate both the encapsulation of drugs and membrane interactions.
